Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy

Diabetes Care. 2004 Aug;27(8):2049-51. doi: 10.2337/diacare.27.8.2049.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Body Mass Index
  • Cardiovascular Diseases / prevention & control*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / enzymology
  • Diabetic Angiopathies / blood
  • Diabetic Angiopathies / prevention & control*
  • Female
  • Humans
  • Hypertension / blood*
  • Hypertension / complications
  • Lipids / blood
  • Male
  • Matrix Metalloproteinase 9 / blood*
  • Middle Aged
  • Reference Values
  • Risk Factors
  • Tissue Inhibitor of Metalloproteinase-1 / blood*
  • Tissue Inhibitor of Metalloproteinase-2 / blood*

Substances

  • Lipids
  • Tissue Inhibitor of Metalloproteinase-1
  • Tissue Inhibitor of Metalloproteinase-2
  • Matrix Metalloproteinase 9